167 related articles for article (PubMed ID: 18499335)
1. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
Chun FK; Suardi N; Capitanio U; Jeldres C; Ahyai S; Graefen M; Haese A; Steuber T; Erbersdobler A; Montorsi F; Huland H; Karakiewicz PI
Eur Urol; 2009 Mar; 55(3):617-28-6. PubMed ID: 18499335
[TBL] [Abstract][Full Text] [Related]
2. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
[TBL] [Abstract][Full Text] [Related]
3. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
4. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.
Abdollah F; Scattoni V; Raber M; Roscigno M; Briganti A; Suardi N; Gallina A; Capitanio U; Freschi M; Salonia A; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2011 Aug; 108(3):366-71. PubMed ID: 21087451
[TBL] [Abstract][Full Text] [Related]
5. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
[TBL] [Abstract][Full Text] [Related]
6. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
[TBL] [Abstract][Full Text] [Related]
7. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
[TBL] [Abstract][Full Text] [Related]
8. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy.
Epstein JI; Sanderson H; Carter HB; Scharfstein DO
Urology; 2005 Aug; 66(2):356-60. PubMed ID: 16040085
[TBL] [Abstract][Full Text] [Related]
9. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
Loeb S; Roehl KA; Thaxton CS; Catalona WJ
Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Graefen M; Ohori M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Erbersdobler A; Henke RP; Huland H; Wheeler TM; Slawin K; Scardino PT; Kattan MW
J Urol; 2004 Jan; 171(1):200-3. PubMed ID: 14665876
[TBL] [Abstract][Full Text] [Related]
11. Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.
Falzarano SM; Zhou M; Hernandez AV; Moussa AS; Jones JS; Magi-Galluzzi C
Urology; 2010 Sep; 76(3):682-7. PubMed ID: 20206973
[TBL] [Abstract][Full Text] [Related]
12. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
13. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
14. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy.
Numao N; Kawakami S; Yokoyama M; Yonese J; Arisawa C; Ishikawa Y; Ando M; Fukui I; Kihara K
Eur Urol; 2007 Dec; 52(6):1663-8. PubMed ID: 17240041
[TBL] [Abstract][Full Text] [Related]
15. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI
BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673
[TBL] [Abstract][Full Text] [Related]
16. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.
Chun FK; Steuber T; Erbersdobler A; Currlin E; Walz J; Schlomm T; Haese A; Heinzer H; McCormack M; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2006 May; 49(5):820-6. PubMed ID: 16439050
[TBL] [Abstract][Full Text] [Related]
17. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
[TBL] [Abstract][Full Text] [Related]
18. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
Haese A; Graefen M; Becker C; Noldus J; Katz J; Cagiannos I; Kattan M; Scardino PT; Huland E; Huland H; Lilja H
Prostate; 2003 Feb; 54(3):181-6. PubMed ID: 12518322
[TBL] [Abstract][Full Text] [Related]
19. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
[TBL] [Abstract][Full Text] [Related]
20. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score.
Coogan CL; Latchamsetty KC; Greenfield J; Corman JM; Lynch B; Porter CR
BJU Int; 2005 Aug; 96(3):324-7. PubMed ID: 16042723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
